{"success":true,"data":{"pressRelease":{"id":"63920","rtpr_id":"nBw3f7k1ya","ticker":"BBNX","exchange":"NASDAQ","all_tickers":["BBNX"],"title":"Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)","author":"Business Wire","published_at":"2026-06-15T14:25:00.097Z","article_body":"Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)\n\nJohnson Fistel, PLLP is investigating potential securities law violations on\nbehalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation\nconcerns whether Beta Bionics or certain of its executive officers made false\nor misleading statements, or failed to disclose material information,\nconcerning the Company’s growth trends, new patient starts, business\noutlook, and related operating metrics.\n\nBeta Bionics Investors: Suffered Losses? Contact Johnson Fistel\n\nIf you purchased Beta Bionics securities and suffered losses, you may have\nlegal rights. Investors are encouraged to join the investigation by visiting:\n\nClick Here to Join the Investigation\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.johnsonfistel.com%2Finvestigations%2Fbeta-bionics-bbnx%2F&esheet=54553987&newsitemid=20260615916529&lan=en-US&anchor=Click+Here+to+Join+the+Investigation&index=1&md5=b4c0c3aa0970b635bbcdf9fb33f15313)\n.\n\nFor more information, contact James Baker at jimb@johnsonfistel.com\n(mailto:jimb@johnsonfistel.com) or (619) 814-4471.\n\nThere is no cost or obligation to participate.\n\nWhy Is Johnson Fistel Investigating Beta Bionics?\n\nThe Beta Bionics investigation focuses on investor losses following the\nCompany’s disclosure of slower new patient start growth for the fourth\nquarter of 2025. New patient starts are an important operating metric for Beta\nBionics, and investors may have relied on the Company’s growth trends and\npublic statements when evaluating the Company’s business prospects.\n\nOn January 8, 2026, Beta Bionics announced preliminary, unaudited financial\nresults and key operating metrics for the fourth quarter of 2025. The Company\nreported that new patient starts were expected to be at least 5,581 for the\nquarter, representing year-over-year growth of at least 36%.\n\nDespite the reported growth, the results were below reported analyst\nexpectations and reflected a significant deceleration from the prior quarter,\nwhen Beta Bionics reported 68% year-over-year growth in new patient starts.\n\nIf you suffered losses in Beta Bionics securities, you are encouraged to\ncontact Johnson Fistel to discuss your legal rights.\n\nAbout Johnson Fistel, PLLP\n\nJohnson Fistel, PLLP is a nationally recognized shareholder rights law firm\nwith offices in California, New York, Georgia, Idaho, and Colorado. The firm\nrepresents individual and institutional investors in shareholder class actions\nand derivative lawsuits.\n\nJohnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by\nISS Securities Class Action Services. In 2024, the firm recovered\napproximately $90,725,000 for investors.\n\nAttorney Advertising. Past results do not guarantee future outcomes. Services\nmay be performed by attorneys in any of our offices. Johnson Fistel, PLLP has\npaid for the dissemination of this promotional communication, and Frank J.\nJohnson is the attorney responsible for its content.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260615916529/en/\n(https://www.businesswire.com/news/home/20260615916529/en/)\n\nJohnson Fistel, PLLP\n\n501 W. Broadway, Suite 800\n\nSan Diego, CA 92101\n\nJames Baker, Investor Relations\n\nFrank J. Johnson, Esq.\n\n(619) 814-4471\n\njimb@johnsonfistel.com (mailto:jimb@johnsonfistel.com) |\nfjohnson@johnsonfistel.com (mailto:fjohnson@johnsonfistel.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw3f7k1ya","title":"Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)","author":"Business Wire","ticker":"BBNX","created":"2026-06-15T14:25:00.097Z","tickers":["BBNX"],"exchange":"NASDAQ","article_body":"Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)\n\nJohnson Fistel, PLLP is investigating potential securities law violations on\nbehalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation\nconcerns whether Beta Bionics or certain of its executive officers made false\nor misleading statements, or failed to disclose material information,\nconcerning the Company’s growth trends, new patient starts, business\noutlook, and related operating metrics.\n\nBeta Bionics Investors: Suffered Losses? Contact Johnson Fistel\n\nIf you purchased Beta Bionics securities and suffered losses, you may have\nlegal rights. Investors are encouraged to join the investigation by visiting:\n\nClick Here to Join the Investigation\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.johnsonfistel.com%2Finvestigations%2Fbeta-bionics-bbnx%2F&esheet=54553987&newsitemid=20260615916529&lan=en-US&anchor=Click+Here+to+Join+the+Investigation&index=1&md5=b4c0c3aa0970b635bbcdf9fb33f15313)\n.\n\nFor more information, contact James Baker at jimb@johnsonfistel.com\n(mailto:jimb@johnsonfistel.com) or (619) 814-4471.\n\nThere is no cost or obligation to participate.\n\nWhy Is Johnson Fistel Investigating Beta Bionics?\n\nThe Beta Bionics investigation focuses on investor losses following the\nCompany’s disclosure of slower new patient start growth for the fourth\nquarter of 2025. New patient starts are an important operating metric for Beta\nBionics, and investors may have relied on the Company’s growth trends and\npublic statements when evaluating the Company’s business prospects.\n\nOn January 8, 2026, Beta Bionics announced preliminary, unaudited financial\nresults and key operating metrics for the fourth quarter of 2025. The Company\nreported that new patient starts were expected to be at least 5,581 for the\nquarter, representing year-over-year growth of at least 36%.\n\nDespite the reported growth, the results were below reported analyst\nexpectations and reflected a significant deceleration from the prior quarter,\nwhen Beta Bionics reported 68% year-over-year growth in new patient starts.\n\nIf you suffered losses in Beta Bionics securities, you are encouraged to\ncontact Johnson Fistel to discuss your legal rights.\n\nAbout Johnson Fistel, PLLP\n\nJohnson Fistel, PLLP is a nationally recognized shareholder rights law firm\nwith offices in California, New York, Georgia, Idaho, and Colorado. The firm\nrepresents individual and institutional investors in shareholder class actions\nand derivative lawsuits.\n\nJohnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by\nISS Securities Class Action Services. In 2024, the firm recovered\napproximately $90,725,000 for investors.\n\nAttorney Advertising. Past results do not guarantee future outcomes. Services\nmay be performed by attorneys in any of our offices. Johnson Fistel, PLLP has\npaid for the dissemination of this promotional communication, and Frank J.\nJohnson is the attorney responsible for its content.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260615916529/en/\n(https://www.businesswire.com/news/home/20260615916529/en/)\n\nJohnson Fistel, PLLP\n\n501 W. Broadway, Suite 800\n\nSan Diego, CA 92101\n\nJames Baker, Investor Relations\n\nFrank J. Johnson, Esq.\n\n(619) 814-4471\n\njimb@johnsonfistel.com (mailto:jimb@johnsonfistel.com) |\nfjohnson@johnsonfistel.com (mailto:fjohnson@johnsonfistel.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-06-15T14:25:00.129304575Z","server_sent_at_ms":1781533500129},"received_at":"2026-06-15T14:25:00.180Z","source_url":"https://www.businesswire.com/news/home/20260615916529/en/"},"analysis":{"id":"53342","press_release_id":"63920","analysis_json":{"industry":{"label":"Medical Devices","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Johnson Fistel issued a shareholder-solicitation notice naming Beta Bionics (BBNX); no new disclosure from the company itself.\n\nThe release is a routine investigation reminder soliciting investors with losses to contact the firm on a contingency basis.\n\nThis is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"firm_recovery_2024":90725000,"q4_2025_new_patient_starts":5581,"q4_2025_patient_growth_yoy":"36%","prior_quarter_patient_growth_yoy":"68%"}},"quotedText":"If you purchased Beta Bionics securities and suffered losses, you may have legal rights.","namedEntities":{"people":[{"name":"James Baker","role":"Investor Relations"},{"name":"Frank J. Johnson","role":"Attorney"}],"products":[],"companies":[{"name":"Johnson Fistel, PLLP","relationship":"plaintiff law firm"},{"name":"Beta Bionics, Inc.","ticker":"BBNX"}],"dollarAmounts":[{"amount":"$90,725,000","context":"amount recovered by Johnson Fistel for investors in 2024"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Johnson Fistel. No new disclosure from the issuer; no certified class, no settlement. Boilerplate investigation reminder."},"tickerRelevance":{"others":[],"primary":"BBNX"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Johnson Fistel issued a shareholder-solicitation notice naming Beta Bionics (BBNX); no new disclosure from the company itself.\n\nThe release is a routine investigation reminder soliciting investors with losses to contact the firm on a contingency basis.\n\nThis is law-firm marketing, not an issuer disclosure or a court action; treat as low-signal noise.","key_figures":{"customDimensions":{"firm_recovery_2024":90725000,"q4_2025_new_patient_starts":5581,"q4_2025_patient_growth_yoy":"36%","prior_quarter_patient_growth_yoy":"68%"}},"named_entities":{"people":[{"name":"James Baker","role":"Investor Relations"},{"name":"Frank J. Johnson","role":"Attorney"}],"products":[],"companies":[{"name":"Johnson Fistel, PLLP","relationship":"plaintiff law firm"},{"name":"Beta Bionics, Inc.","ticker":"BBNX"}],"dollarAmounts":[{"amount":"$90,725,000","context":"amount recovered by Johnson Fistel for investors in 2024"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-15T14:25:25.023Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":24841,"modelName":"george-droid-qwen-72b"}}